Consensus perspectives on prophylactic therapy for haemophilia:: summary statement

被引：179

作者：

Berntorp, E ^{[1
]}

Astermark, J

Björkman, S

Blanchette, VS

Fischer, K

Giangrande, PLF

Gringeri, A

Ljung, RC

Manco-Johnson, MJ

Morfini, M

Kilcoyne, RF

Petrini, P

Rodriguez-Merchan, EC

Schramm, W

Shapiro, A

Van Den Berg, HM

Hart, C

机构：

[1] Malmo Univ Hosp, Dept Coagulat Disorders, SE-20502 Malmo, Sweden

[2] Malmo Univ Hosp, Hosp Pharm, SE-20502 Malmo, Sweden

[3] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada

[4] Univ Med Ctr Utrecht, Van Creveldklin, Utrecht, Netherlands

[5] Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England

[6] IRCCS Maggiore Hosp, Dept Internal Med, Haemophilia & Thrombosis Ctr, Milan, Italy

[7] Univ Milan, Milan, Italy

[8] Malmo Univ Hosp, Dept Paediat, SE-20502 Malmo, Sweden

[9] Mt States Reg Hemophilia & Thrombosis Ctr, Aurora, CO USA

[10] Azienda Osped Careggi, Hemophilia Ctr, Florence, Italy

[11] Univ Colorado, Hlth Sci Ctr, Denver, CO USA

[12] Karolinska Hosp, Dept Paediat Coagulat Disorders, S-10401 Stockholm, Sweden

[13] La Paz Univ Hosp, Haemophilia Ctr, Madrid, Spain

[14] La Paz Univ Hosp, Serv Traumatol & Orthopaed, Madrid, Spain

[15] Klinikum Univ Munchen, Int Hemophilia Ctr, Munich, Germany

[16] Indiana Hemophilia & Thrombosis Ctr Inc, Indianapolis, IN USA

[17] InforMED Inc, Narberth, PA USA

来源：

HAEMOPHILIA | 2003年 / 9卷

关键词：

haemophilia; diagnosis; treatment; guidelines;

D O I：

10.1046/j.1365-2516.9.s1.17.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the conference. In the consensus, participants agreed upon revised definitions for primary and secondary prophylaxis and also made recommendations concerning the need for an international system of pharmacovigilance. Considerations on starting prophylaxis, monitoring outcomes, and individualizing treatment regimens were discussed. Several research questions were identified as needing further investigation, including when to start and when to stop prophylaxis, optimal dosing and dose interval, and methods for assessment of long-term treatment effects. Such studies should include carefully defined cohorts, validated orthopaedic and quality-of-life assessment instruments, and cost-benefit analyses.

引用

页码：1 / 4

页数：4